Save
Molecular actions of heparin and their implications in preventing pre‐eclampsia
Author(s): ,
J. M. Wat
Affiliations:
Research Centre for Women's and Infant's Health, Lunenfeld‐Tanenbaum Research Institute, Toronto, Canada. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
,
M. C. Audette
Affiliations:
Research Centre for Women's and Infant's Health, Lunenfeld‐Tanenbaum Research Institute, Toronto, Canada. Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada
J. C. Kingdom
Affiliations:
Research Centre for Women's and Infant's Health, Lunenfeld‐Tanenbaum Research Institute, Toronto, Canada. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada. Department of Obstetrics and Gynaecology, Sinai Health System, Toronto, Canada
Correspondence: John C. Kingdom, Department of Obstetrics and Gynaecology, Room 3‐904, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5|Tel.: +1 416 586 8764|E‐mail: john.kingdom@sinaihealthsystem.ca
ISTH Academy. C. Kingdom J. Aug 2, 2018; 227430
John C. Kingdom
John  C. Kingdom

Access to Premium content is currently a membership benefit.


Click here to join ISTH or renew your membership.

Journal Abstract
Discussion Forum (0)
Rate & Comment (0)



Pre‐eclampsia, a hypertensive disorder of pregnancy, continues to be a significant cause of global maternal morbidity. Low‐dose aspirin remains the only standard‐of‐care prophylactic therapy for preventing pre‐eclampsia, but is limited in efficacy. Heparin and its derivatives may further enhance the efficacy of aspirin therapy to prevent pre‐eclampsia, but the mechanisms mediating this augmentative effect are not known. Although heparin is an anticoagulant agent, it also possesses many anticoagulant‐independent properties that may be relevant in the prevention of pre‐eclampsia, including effects on placental, vascular and inflammatory function. This review summarizes the non‐anticoagulant properties of heparin, and extrapolates how these actions may influence the trajectory of pre‐eclampsia pathogenesis as a means of pathway‐specific therapy.
Keyword(s)
endothelium, heparin, inflammation, placenta, pre‐eclampsia
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings